Treatment of invasive fungal infections in cancer patients-Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

Angelika Böhme, Markus Ruhnke, Dieter Buchheidt, Oliver A. Cornely, Herrmann Einsele, Ruxandra Enzensberger, Holger Hebart, Werner Heinz, Christian Junghanss, Meinolf Karthaus, et al.

► To cite this version:

Angelika Böhme, Markus Ruhnke, Dieter Buchheidt, Oliver A. Cornely, Herrmann Einsele, et al.. Treatment of invasive fungal infections in cancer patients-Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Annals of Hematology*, 2008, 88 (2), pp.97-110. 10.1007/s00277-008-0622-5 . hal-00477985

HAL Id: hal-00477985

<https://hal.science/hal-00477985>

Submitted on 30 Apr 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

Angelika Böhme · Markus Ruhnke · Dieter Buchheidt ·
Oliver A. Cornely · Herrmann Einsele ·
Ruxandra Enzensberger · Holger Hebart ·
Werner Heinz · Christian Junghanss ·
Meinolf Karthaus · William Krüger · Utz Krug ·
Thomas Kubin · Olaf Penack · Dietmar Reichert ·
Stefan Reuter · Gerda Silling · Thomas Südhoff ·
Andrew J. Ullmann · Georg Maschmeyer

Received: 9 September 2008 / Accepted: 23 September 2008 / Published online: 14 October 2008
© Springer-Verlag 2008

Abstract Invasive fungal infections are a main cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens. Early antifungal treatment is mandatory to improve survival. Today, a number of

effective and better-tolerated but more expensive antifungal agents compared to the former gold standard amphotericin B deoxycholate are available. Clinical decision-making must consider results from numerous studies and published

A. Böhme (✉)
ONKOLOGIKUM, Frankfurt am Museumsufer,
Schaubstraße 16,
60596 Frankfurt, Germany
e-mail: angelika.boehme@onkologikum.de

M. Ruhnke
Abt. Onkologie und Hämatologie, Med. Klinik u. Poliklinik II,
Charité Universitätsmedizin, Campus Charité Mitte,
Charitéplatz 1,
10117 Berlin, Germany

D. Buchheidt
III. Medizinische Klinik, Universitätsklinikum Mannheim GmbH,
Theodor-Kutzer-Ufer 1–3,
68167 Mannheim, Germany

O. A. Cornely
Klinik I für Innere Medizin und Zentrum für Klinische Studien
(ZKS) 01KN0706, Klinikum der Universität Köln,
Kerpener Str. 62,
50937 Köln, Germany

H. Einsele
Medizinische Klinik und Poliklinik II,
Universitätsklinikum Würzburg,
Josef-Schneider-Str. 2,
97080 Würzburg, Germany

R. Enzensberger
Institut für Medizinische Mikrobiologie und Krankenhaushygiene,
J.W. Goethe-Universität,
Paul-Ehrlich-Str.40,
60596 Frankfurt, Germany

H. Hebart
Zentrum für Innere Medizin,
Klinikum Schwäbisch Gmünd/Stauferklinik,
Wetzgauer Str. 85,
73557 Mutlangen, Germany

W. Heinz
Schwerpunkt Infektiologie, Medizinische Klinik und Poliklinik II,
Universitätsklinikum Würzburg,
Josef-Schneider-Straße 2,
97080 Würzburg, Germany

C. Junghanss
Abt. Hämatologie und Onkologie. Klinik und Poliklinik für Innere
Medizin, Universität Rostock,
Ernst-Heydemann-Str. 6,
18057 Rostock, Germany

M. Karthaus
Abt. Hämatologie/Onkologie, St. Klinikum München-Neuperlach,
Oskar-Maria-Graf-Ring 51,
81737 München, Germany

guidelines, as well as licensing status and cost pressure. New developments in antifungal prophylaxis improving survival rates result in a continuous need for actualization. The treatment options for invasive *Candida* infections include fluconazole, voriconazole, and amphotericin B and its lipid formulations, as well as echinocandins. Voriconazole, amphotericin B, amphotericin B lipid formulations, caspofungin, itraconazole, and posaconazole are available for the treatment of invasive aspergillosis. Additional procedures, such as surgical interventions, immunoregulatory therapy, and granulocyte transfusions, have to be considered. The Infectious Diseases Working Party of the German Society of Hematology and Oncology here presents its 2008 recommendations discussing the dos and do-nots, as well as the problems and possible solutions, of evidence criteria selection.

Keywords Cancer · Invasive fungal infections · Antifungals

Introduction

Invasive fungal infections represent a primary cause of morbidity and mortality in cancer patients. In particular, invasive infections caused by *Aspergillus* species are increasing complications of intensive chemotherapy regimens. In Germany, the substances currently approved for use in the systemic therapy of invasive fungal infections are amphotericin B deoxycholate (D-AmB), liposomal AmB (L-AmB), amphotericin B lipid complex (ABLC), fluconazole, itraconazole, 5-flucytosin, caspofungin, anidulafun-

gin, voriconazole, and posaconazole. The Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology actualized the recommendations from 2003 [7] based on EBM criteria proposed by the Infectious Diseases Society of America (IDSA) [42]. Special aspects of fungal septicemia or fungal infections in allogeneic bone marrow/stem cell transplant recipients, which are published in separate manuscripts [22, 80], are not considered in this article.

Methods

Data Clinical studies and guidelines published in English were searched on Medline from 1990 up to June 2008. The data were selected by the first author and edited by the coauthors. Databases and randomized or well-designed nonrandomized controlled clinical trials for invasive *Candida* or *Aspergillus* infections that included more than 50 patients were considered. Studies of treatment for mixed invasive fungal infections involving a minimum of 25 patients with invasive *Candida* infections or aspergillosis were evaluated. Retrospective analyses in rare infection types, such as hepatosplenic candidosis or mucormycosis included at least 20 patients. Fungal infections in allogeneic stem cell transplant patients, which have special aspects of risk/prognostic factors and comedication problems, were not considered. *Pneumocystis jirovecii*, which affiliates to the fungal pathogens as well, has not been included since epidemiology and treatment options are completely different compared to other invasive mycoses.

W. Krüger
Medizinische Klinik C, Ernst-Moritz-Arndt-Universität,
Ferdinand-Sauerbruch-Str.,
17487 Greifswald, Germany

U. Krug
Medizinische Klinik A, Medizinische Universitätsklinik,
Albert-Schweitzer-Str. 33,
48149 Münster, Germany

T. Kubin
Hämatologie/Onkologie, Klinikum Traunstein,
Cuno-Niggel-Straße 3,
83278 Traunstein, Germany

O. Penack
Klinik für Hämatologie und Onkologie,
Charité, Campus Benjamin Franklin,
Hindenburgdamm 30,
12200 Berlin, Germany

D. Reichert
Hämatologisch-Onkologische Gemeinschaftspraxis Dr. Reichert/
Dr. Janssen,
Kuhlenstraße 53d,
26655 Westerstede, Germany

S. Reuter
Klinik für Gastroenterologie, Hepatologie und Infektiologie,
Universitätsklinikum Düsseldorf,
Moorenstraße 5,
40225 Düsseldorf, Germany

G. Silling
Innere Medizin A, Med. Universitätsklinik,
Albert-Schweitzer-Str. 33,
48149 Münster, Germany

T. Südhoff
II. Medizinische Klinik, Klinikum Passau,
Innstraße 76,
94032 Passau, Germany

A. J. Ullmann
3. Medizinische Abteilung, Johannes Gutenberg-Universität,
Langenbeckstr. 1,
55131 Mainz, Germany

G. Maschmeyer
Medizinische Klinik, Hämatologie und Onkologie,
Klinikum Ernst von Bergmann,
Charlottenstraße 72,
14467 Potsdam, Germany

Evidence criteria Wherever possible, evidence categories of the IDSA were integrated (Table 1) [42]. Recommendations for treatment in neutropenic patients, however, are problematic for substances that are only or mainly studied in nonneutropenic patients but are already widely and successfully used in clinical practice. Evidence levels give only a reflection of study activities and are not always correlated with practice and experience. The IDSA guidelines for the treatment of invasive *Candida* infections published in 2004 avoid this dilemma, giving their recommendations without any rating [77]. The new guidelines, however, presented at Interscience Conference on Antimicrobial Agents and Chemotherapy 2007, decide on “down-grading” of recommendation levels for substances proved only or mainly in nonneutropenic patients. The first European Conference on Infections in Leukemia proceeded in a similar manner [35]. The AGIHO subgroup “Treatment of fungal infections” agreed on the following procedure: Study data are the basis for recommendation levels, since we assume an analog antifungal efficacy, but we added the mark “only” or “mainly proven for nonneutropenic patients.” In contrast to other consensus groups, the AGIHO subgroup decided to assess not only the efficacy but also the tolerability of substances.

Assessment of license Principally, we do not consider the status of license for our recommendations and recommend the substances in accordance with study data. We urgently want to point out that the state of license must not be mixed up with the degree of efficacy. On the other hand, the availability of less expensive treatment modalities may put a high pressure on physicians to decide on off-label use. One should consider, however, that off-label use of medications given without necessity or without evidence for clear superiority compared to the licensed substances may cause legal problems in the case of severe complications or death by treatment failure.

Finding consensus These recommendations were first prepared by a panel of experts in the field of infections in

immunocompromised patients. In a second step, the manuscript was reviewed by the AGIHO subgroup “Treatment of fungal infections” and finalized by AGIHO Consensus Group. We point out that the responsibility for selected therapy is exclusively that of the ordering physician.

Invasive *Candida* infections

Invasive *Candida* infections in cancer patients are primarily caused by *Candida albicans*, although an increase of candidemia by non-*albicans Candida* spp. has partially been found in patients with hematological malignancies [30, 110]. Due to high mortality, especially in patients with delayed sufficient treatment [24], antifungal treatment should be started in neutropenic patients as soon as possible. Study data for neutropenic patients, however, are limited.

Azoles

Fluconazole In noncomparative trials, observational studies and larger randomized trials, including mainly nonneutropenic patients, fluconazole demonstrated a high efficacy rate [2, 66, 82, 90]. Compared to D-AmB, fluconazole was not inferior and showed significantly better tolerability (AI) [2, 82, 90], but lower efficacy compared to anidulafungin [89]. Additionally, the incidence of invasive *Candida* infections with primary fluconazole resistance like *Candida krusei* or reduced susceptibility like *Candida glabrata* is rising in hematological patients [30, 110]; therefore, an echinocandin should be preferred, even if mainly proven in nonneutropenic patients (AI). A switch to fluconazole is possible if a susceptible species has been confirmed and the patient is clinically stable and has no prior azole exposure. Initially, fluconazole 800 mg/day should be preferred and may be reduced to 400 mg/day if the patient is clinically stable and not neutropenic (AII) [26, 77, 91].

Table 1 Categories indicating the strength of each recommendation for or against its use, and grades indicating the quality of evidence on which recommendations are based

A	Good evidence to support a recommendation for use
B	Moderate evidence to support a recommendation for use
C	Poor evidence to support a recommendation for use
D	Moderate evidence to support a recommendation against use
E	Good evidence to support a recommendation against use
I	Evidence from at least 1 properly randomized, controlled trial
II	Evidence from at least 1 well-designed clinical trial without randomization, from cohort or case-controlled analytic studies (preferably from more than one center), from multiple time series, or from dramatic results of uncontrolled experiments
III	Evidence from opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees

Criteria of the IDSA [1]

Itraconazole A study comparing itraconazole with fluconazole in invasive *Candida* infections of nonneutropenic patients has been stopped since only a few patients reached the endpoint (data published only in abstract format). Other data about itraconazole are very limited (CIII).

Voriconazole In nonneutropenic patients, voriconazole resulted in similar success and significantly better tolerability compared to D-AmB followed by fluconazole (AI) [46]. Voriconazole may be given safely to patients without neutropenia with refractory infections or resistant *Candida* spp. [70].

Posaconazole There are no sufficient data for posaconazole [CIII].

Echinocandins

Caspofungin In a large randomized study also including neutropenic patients, caspofungin demonstrated similar efficacy and significantly fewer side effects compared to D-AmB (AI) [63]. Due to its good efficacy against non-*C. albicans* spp., as well as its good safety profile, caspofungin may be regarded as the drug of choice in severely ill, clinically instable patients with organ dysfunction, especially in patients with neutropenia.

Micafungin A noncomparative trial of micafungin for 126 newly diagnosed and refractory candidemias resulted in an 85% success rate for adults [69]. A recently published study, including mainly nonneutropenic patients, demonstrated an equally high efficacy and a higher tolerability of micafungin compared to L-AmB in the first-line therapy of invasive *Candida* infections (AI) [47]. A large randomized study (also small numbers of neutropenic patients) resulted in equal efficacy of micafungin 150 vs 100 mg/day vs caspofungin [78].

Anidulafungin In a randomized study including less than 5% neutropenic patients, anidulafungin resulted in higher clinical efficacy and clearance of *Candida* bloodstream infection compared to fluconazole. The authors discussed a potential influence of a center effect but could not find an influence on the study endpoints. Anidulafungin fulfilled the criteria for noninferiority (AI) [89].

Amphotericin B formulations

Amphotericin B lipid complex (ABLC) ABLC is effective in the second-line therapy of invasive *Candida* infections shown in emergency use study and a large mycoses database (CLEAR) (AII) [41]. A randomized study com-

paring ABLC vs D-AmB, also including neutropenic patients, showed similar efficacy and better tolerability of ABLC, but the definite study results are not published.

Liposomal Amphotericin B (L-AmB) The above mentioned randomized study comparing L-AmB with micafungin for first-line treatment demonstrated a high efficacy but lower tolerability of L-AmB in invasive *Candida* infections, but mainly nonneutropenic patients had been included (AI) [47]. An analysis of eight open-label studies on D-AmB and AmB lipid formulations showed an efficacy rate of 75% in ABLC-treated and 80% in L-AmB-treated patients with candidiasis [71]. L-AmB may be given as second-line therapy (AII).

Amphotericin B colloidal dispersion (ABCD) ABCD is unavailable in Germany. The tolerability is lower compared to that of ABLC or L-AmB.

Amphotericin B deoxycholate (D-AmB) Randomized studies did not demonstrate an advantage of D-AmB compared to fluconazole, caspofungin, voriconazole, or AmB lipid formulations [2, 46, 63, 66, 71, 82, 90]. The main disadvantages of D-AmB are nephrotoxicity, hypokalemia, and infusion-related adverse events. An increasing number of publications reported long-term nephrotoxicity with D-AmB interfering with nephrotoxic medications especially in stem cell-transplanted patients [33, 46, 61], partially resulting in inferior survival [33, 61]. In a recently published prospective study of 418 patients, treatment with D-AmB vs L-AmB vs ABLC or ABCD resulted in a deterioration of kidney function in 66% vs 30% vs 55% [108]. So, in contrast to other authors, we clearly recommend avoidance of D-AmB for routine use (EI).

Combinations

In nonneutropenic patients, the combination of D-AmB for 5–6 days and fluconazole 800 mg/day showed no antagonism, a similar mortality, but improved clinical outcome and more rapid eradication of yeasts from bloodstream compared to fluconazole alone (AI) [91]. In cancer patients, there are no data about combination therapies in patients with invasive *Candida* infections.

Central venous catheter

Central venous catheters should be removed if presumed to be causative for *Candida* infection (BII) [77, 87, 114]. In vitro data suggest that echinocandins or L-AmB are more effective against biofilms [13]. This would support the idea to avoid a removal, but clinical data are lacking to support this approach. One recent paper hypothesizes that candidemias

in neutropenic patients derives from colonization in the gastrointestinal tract and less from central venous catheters [87].

Duration of treatment and maintenance therapy

Duration of treatment in nonneutropenic patients is recommended for at least 14 days after the first negative blood culture and resolution of signs and symptoms of candidemia (BIII) [77] but should be adapted to possible organ manifestations. In the case of a proven (fluconazole sensitive) invasive *Candida* infection, an initial therapy with an i.v. antifungal agent followed by oral fluconazole or voriconazole has been shown to be feasible.

Hepatosplenic candidosis

If fever persists after neutrophil recovery, hepatosplenic candidosis should be considered in hematological patients. Treatment experience is mainly available for D-AmB and fluconazole, showing response rates of more than 50% of cases [1, 3, 15, 21, 74, 98], but caspofungin is today accepted as alternative therapy when the *Candida* species is not identified [77, 105]. If *Candida* spp. are susceptible, fluconazole is recommended for primary therapy in clinically stable patients who are no longer neutropenic (BIII). For neutropenic patients, AmB lipid formulations or caspofungin may be given (BIII); less data exist for voriconazole (CIII). Due to the high risk of relapse in cancer patients, antifungal therapy should be given until there is a calcification or complete remission of the lesions, frequently several months are necessary (BIII). In stable patients, intravenous therapy may be switched to oral medication. However, this has not been studied so far.

Other manifestations

Candida infections of the central nervous system, usually caused by hematogenic dissemination, are infrequent in adults. Based on studies in children, the most recommended treatment for *Candida* meningitis is D-AmB in combination with 5-flucytosine. Case reports of patients treated with L-AmB and fluconazole are available in small numbers. Animal studies show a better penetration of L-AmB into the brain tissue as compared to ABLC [29]. Due to its good permeability into the cerebrospinal fluid, voriconazole may be a potential alternative. Treatment should be continued for an additional 4 weeks following the resolution of manifestations (BIII) [73, 77]. In brain abscess cases, additional drainage or, if possible, surgical resection is recommended. Renal *Candida* infections (infiltrations) are usually caused by blood stream infection and should be treated in the same manner. For urinary *Candida* infection,

fluconazole has been proven in mainly nonneutropenic patients and is the drug of choice, if a susceptible *Candida* spp. is cultured (AI) [52, 104]. If a urine catheter is in place, it should be removed whenever possible (BII) [77]. The treatment options for invasive candidosis are summarized in Table 2.

Infections by *Aspergillus* species

In neutropenic patients, invasive pulmonary aspergillosis (IPA) is the most frequent manifestation (80–90%). The fatality rate is 30–60% [34, 58, 72]. Early treatment at first signs of infection is mandatory and can improve the chance of survival (BIII) [11, 43]. For primary and secondary treatment of invasive aspergillosis, voriconazole, D-AmB, AmB lipid formulations, caspofungin, itraconazole, and posaconazole have been proven to be effective.

Azoles

Voriconazole In an open, noncomparative study, voriconazole showed a response rate of 59% in the primary treatment of invasive aspergillosis and a 38% rate when used for salvage treatment [20]. In a large, randomized study including mainly cancer patients, the therapy with

Table 2 Therapy of main invasive *Candida* infections in patients with hematooncological malignancies

Primary treatment for candidemia
Echinocandins ^a : AI
Liposomal AmB: AI
Voriconazole ^b : AI
If the patient is stable and not neutropenic + susceptible <i>Candida</i> spp +no prior azole exposure: fluconazole 800 mg/day (dose reduction to 400 mg in responders): AI
Itraconazole and posaconazole: CIII
Conventional AmB: EI ^c
Secondary treatment:
Liposomal AmB or amphotericin B Lipid complex: AII
Voriconazole, echinocandins: BIII
Hepatosplenic candidiasis:
Clinically stable patients with normal neutrophils, without prior azole exposure: fluconazole 800 mg/day: BIII
In responders: reduction to 400 mg/day: BIII
Neutropenic or unstable patients:
Liposomal AmB/AmB lipid complex: BIII
Echinocandins: BIII
Voriconazole: CIII

AmB amphotericin B

^a Proven mainly for nonneutropenic patients

^b Proven only for nonneutropenic patients

^c Conventional AmB is no longer recommended as first-line antifungal agent due to significant higher toxicity with equal clinical efficacy as compared to all other compounds studied in randomized trials.

voriconazole compared to D-AmB (both followed by other licensed antifungal therapy in the case of failure/intolerance) demonstrated a significantly higher response and survival rate with fewer *Aspergillus*-related deaths and side effects, which resulted in the establishment of voriconazole as new gold standard [34] (AI). Although the study design has been questioned and improvements have been suggested, we recommend voriconazole as standard therapy for aspergillosis [AI]. In addition, compared to AmB, voriconazole is more active in vitro against *Aspergillus terreus* [32, 49]. After oral or intravenous administration, voriconazole concentrations are adequate in all body sites, including brain parenchyma [28], but a large variability in trough plasma levels has been observed [79]. Main complications are reversible visual disturbances in up to 40% of patients. Primarily due to cytochrome P450 metabolism, voriconazole may interact with a large number of other drugs. Therefore, contraindications and comedications (e.g., vinca alkaloids, statins, chinidins) have to be closely monitored. Oral and intravenous formulations are available.

Posaconazole Posaconazole was licensed in Germany for second-line therapy of aspergillosis in 2005. In a retrospective comparison of posaconazole vs standard treatments in a historical control group, patients (also including neutropenic) demonstrated a response of 42% vs 26%, respectively; the response to posaconazole was associated with plasma concentrations [113]. The response rate of posaconazole compared to high-dose AmB lipid formulations (≥ 7.5 mg/kg) or caspofungin plus high-dose lipid-AmB in salvage therapy for invasive aspergillosis was 40% vs 8% vs 11%, respectively, in a total of 143 patients with hematological malignancies [88]. Thus, posaconazole is recommended as salvage therapy (AII). While posaconazole was generally well tolerated, also in long-term use [86], its metabolism via cytochrome P450-system, however, has to be considered if comedications are necessary. Posaconazole is also efficacious in zygomycosis, which is frequently not distinguishable from aspergillosis in imaging procedures of lungs, paranasal sinuses, or brain. Posaconazole is only available as an oral suspension.

Itraconazole No appropriate studies with sufficient patient numbers have been conducted. For therapy of IPA in patients with persistent immunosuppression, the administration of an intravenous formulation is preferable, as this ensures a more rapid response (BIII) [106]. In a non-comparative study involving a limited number of patients, intravenous itraconazole followed by oral administration showed a response rate of 48% but had to be discontinued due to intolerability in one third of the patients [10]. Randomized studies comparing intravenous itraconazole

with polyenes or other azoles in patients with IPA are not available. Since more potent and adequately investigated substances are available, itraconazole may only play a role if none of these other substances are tolerated (BIII).

Echinocandins

Caspofungin Therapy with caspofungin resulted in a response rate of 45%–49% in noncomparative salvage therapy studies of patients with invasive aspergillosis and failure of or intolerability to standard antifungal therapy [55, 64]. A case collection of 118 patients demonstrated a response rate of 61% [25]. Limited experiences in first-line treatment are available. Additionally, this therapy is proved to be very well tolerated and is recommended as salvage therapy (AII).

Micafungin Micafungin has been investigated in a mostly salvage therapy study as monotherapy and, particularly, combination therapy, which resulted in efficacy rates of about 36% [19]. The relevance of micafungin for the treatment of IA cannot be assessed as of yet (CIII).

Anidulafungin Data on anidulafungin in the treatment of invasive aspergillosis are very limited.

Amphotericin B formulations

Amphotericin B lipid complex (ABLC) A large database (CLEAR/Collaborative Exchange of Antifungal Research) showed a 44% efficacy in about 400 patients with aspergillosis (55% response in 42 neutropenic patients) [14], and 31% response in patients after allogeneic stem cell transplantation [40], mainly in patients with second-line therapy (AII).

Liposomal amphotericin B (L-AmB) In several noncomparative studies with L-AmB for second-line therapy, which, however, included only smaller patient numbers, each resulted in response rates of 50–70% [62, 92]. A pooled efficacy analysis resulted in a response rate of 47% in invasive aspergillosis [16]. In a randomized study, L-AmB was equally effective compared to D-AmB in the first-line therapy of invasive mycosis [50], but the study was not restricted to aspergillosis as well as the second-line use studies. The efficacy of L-AmB vs ABLC in the first-line therapy has been compared by an analysis of eight open label studies with more than 1,000 patients, resulting in a response of 61% vs 46% [71]. Most studies show that ABLC is more toxic. A retrospective study in 158 consecutive patients with mainly acute leukemia or allogene-

neic stem cell transplantation receiving L-AmB or ABLC for invasive aspergillosis resulted in a very poor outcome of both drug groups (12%), but about 25% of patients had a persistent neutropenia, 40% a history of transplantation and about 85% a use of corticosteroids. ABLC was associated with significantly higher nephrotoxicity compared to L-AmB [31]. The studied dosages of L-AmB for treatment of invasive aspergillosis are 1–10 mg/kg/day (manufacturer recommendation: 1–3 mg/kg) [17, 23, 50]. A randomized study comparing L-AmB 4 vs 1 mg/kg resulted in similar efficacy rates, but survival at day 14 and response in patients with proven aspergillosis was higher in the 4-mg/kg arm [23]. A randomized comparison of L-AmB 3 vs 10 mg/kg (mainly cancer patients) in primary therapy of aspergillosis showed equal efficacy and higher toxicity of the higher dosage [17], the response rate is comparable to voriconazole. We recommend L-AmB as primary therapy with less strength (AII), since the trial did not compare L-AmB with a standard treatment. Dosages higher than 3 mg/kg are not necessary (AI). L-AmB may be also used as second-line treatment (AII).

Amphotericin B deoxycholate (D-AmB) Until 2002, intravenous therapy with D-AmB had been the therapeutic gold standard with response rates of 30–50%. Maximum tolerable daily dosages of up to 1.5 mg/kg have been recommended [106]. Comparative clinical studies on dose regimens are, however, not available. In the case of a good partial response, the therapy had been frequently switched to oral itraconazole in order to facilitate outpatient treatment; however, there are no formal studies confirming this approach (CIII). Due to its high toxicity (see the chapter “invasive candidosis”) and without any clinical evidence for superiority compared to the newer highly-potent antifungals, we strongly recommend avoiding D-AmB (EI) [34].

Combinations

The benefit of a combination of D-AmB plus 5-flucytosine has not been substantiated by appropriate clinical trials. There are limited data, which show a response rate of 42% for combinations of L-AmB and caspofungin as primary or salvage therapy [44], 55% for combinations with caspofungin + polyenes or triazoles in cancer patients [54], and a significantly reduced mortality rate for patients receiving caspofungin plus voriconazole vs voriconazole alone in refractory aspergillosis among stem cell transplant recipients [56]. A recently published randomized pilot-study comparing combination of L-AmB plus caspofungin (standard dosages) to high-dose L-AmB in patients with hematological malignancies resulted in a better response with the combination at the end of treatment but similar overall survival after

12 weeks, and the patient number (30) was very small [12]. The data are very limited, so combinations should be restricted to controlled clinical trials and may be considered for refractory disease and severely ill patients (CIII).

Duration of treatment

Generally, the antifungal therapy should be continued until the manifestations of IPA have been completely resolved or are reduced to residual scarring (BIII). Before the first clinical response assessment, a minimum of 14 days of full-dose treatment is recommended. Apart from clearly evident failure due to resistance of the pathogen (e.g., *A. terreus* to AmB), lack of adequate drug levels at the site of infection, intolerance, or severe organ toxicity, nonresponse of IA to an established antifungal therapy during this period should be stated with caution [57]. A temporary increase in the volume of pulmonary lesions during the first week of treatment or neutrophil recovery should not be misinterpreted as antifungal treatment failure.

Specific manifestations

Aspergillus sinusitis predominantly occurs in allogeneic stem cell transplant recipients (2–3%) and is primarily caused by *Aspergillus fumigatus* or *Aspergillus flavus* [102, 109]. Frequently, additional surgical intervention is required (BIII) [106], resulting in a higher survival rate. Overall, aspergillus sinusitis has been associated with a relatively low mortality rate of 26.1% [53]. For therapy recommendations, see IPA. While meningitis is rarely caused by *Aspergillus* spp., brain abscesses after allogeneic stem cell transplantation are most often caused by *A. fumigatus* or *A. flavus*. Comparable studies regarding drug treatment do not exist. The prior standard therapy with D-AmB is not effective [18]. The combination with 5-flucytosine (suggested due to its good blood–brain barrier penetration), has not been studied in controlled clinical trials (CIII). Due to its good permeability into the cerebrospinal fluid, voriconazole is recommended for primary treatment [94] and has shown a survival of 8 in 19 patients [20]. Single case reports describe an additional intrathecal and intracavitary administration of AmB; however, this therapy is presently not approved and the efficacy has not been appropriately validated. Successful therapy with L-AmB has also been reported in clinical trials. In animal models, L-AmB demonstrated superior penetration into brain tissue when compared to D-AmB, especially when given in higher doses. A retrospective study of 81 patients with CNS aspergillosis resulted in significantly better survival in patients undergoing surgery [99]. So, if feasible, surgical resection of singular lesions is recommended (AII). Drainage of epidural abscesses is also suggested (BIII) [106]. Cutaneous aspergillosis is a rare variant of invasive

Aspergillus infection [111]. *Aspergillus flavus* and *A. fumigatus* are the most frequent causative agents. Therapy should be initiated early and, due to missing specific trials, recommendations have to be deduced from those for IPA. In case of necrosis, surgical wound debridement should be considered (BIII) [106].

Aspergilloses occurring under posaconazole or voriconazole prophylaxis Recommendations for the treatment of invasive mycoses have to consider the prophylactic regimens, but so far, experiences or studies in this field are lacking. Therefore, the expert group recommends the switch to another class of antifungal agents (BIII).

Therapy recommendations for invasive aspergillosis are summarized in Table 3.

Most recently published updated IDSA guidelines for aspergillosis recommended voriconazole, but in contrast to our grading, L-AmB has also been recommended for first-line therapy of IPA with the level AI [112]. For salvage therapy, we agree to level AII for L-AmB but explicitly favor posaconazole (AII) and caspofungin (AII) to micafungin (insufficient data; CIII) or itraconazole (less well studied and tolerated than posaconazole; BIII). The IDSA assessed all these compounds with the level BII.

***Cryptococcus neoformans* infections**

Cryptococcosis is rare in cancer patients [45, 60]. However, an infection may occur along with T-cell defects or following a CD4-lymphocyte-depleting therapy. D-AmB (0.7–1 mg/kg) plus 5-flucytosine (100 mg/kg) for 2 weeks

followed by maintenance therapy with fluconazole 400 mg/day for 10 weeks is the recommended antifungal treatment of cryptococcal meningitis in HIV-infected patients (see Table 4) (AI) [5, 8, 38, 84, 95]. Data about AmB lipid formulations are limited. Initial treatment with L-AmB (4 mg/kg/day) compared to D-AmB (0.7 mg/kg/s), both followed by fluconazole, showed a more rapid eradication of *Cryptococcus* from the cerebrospinal fluid within the first 14 treatment days (AI) [51]. ABLC demonstrated a total response of 66% in 101 patients, 75% in 44 cases of first-line therapy (BII) [4]. Posaconazole was effective in 14 from 29 patients [83]; voriconazole data are very limited (CIII). In isolated pulmonary cryptococcosis, fluconazole 200–400 mg for 6–12 months may be sufficient (AIII) [45, 95]; alternatively, itraconazole 200–400 mg may be used (BIII). Treatment should be continued for at least 12 weeks and prolonged in case of delayed response (positive culture of cerebrospinal fluid after 2 weeks of therapy) (CIII). The duration of maintenance therapy should consider the individual immune status of the patient.

Zygomycosis

Zygomycosis is a rare disease with a fatality rate up to 90% in neutopenic patients [75], who have mainly pulmonary manifestations [93]. Recently, reports on breakthrough zygomycoses in patients with voriconazole therapy have been published. In a retrospective survey of 59 cases, L-AmB was found to be a favorable prognostic factor [75]. Attempts to achieve high concentrations of AmB at the site of infection might be beneficial, but there is a lack of solid data on daily dosages required for effective therapy. Experts recommended L-AmB with doses of at least 5 mg/kg (BIII). ABLC showed a response of 72% in 64 immunosuppressed patients [48]. Additional surgical intervention resulted in a lower fatality rate as compared with antifungal therapy alone (11% vs. 60%) (BIII) [75, 107]. Twelve of 20 patients using ABCD had a favorable outcome [36]. The benefit of combination is unclear. In salvage treatment, posaconazole is effective with response rates of about 50–80% [9, 27].

Table 3 Therapy of aspergillus infections in hematological patients

Primary treatment of IPA
Voriconazole: AI, switch to oral therapy if clinically justified
Liposomal AmB: AII, dosage 3 mg/kg; AI
Conventional AmB: EI
Secondary treatment:
Generally: switch to another class of substance
Caspofungin: AII
Posaconazole: AII
ABLC: BII
Itraconazole: only if no other <i>aspergillus</i> -effective substance may be tolerated: BIII
Micafungin: CIII
Sinusitis: see IPA, + surgical intervention, if indicated: BIII ^a
CNS: voriconazole (see IPA), alternatively high dose L-AmB (at least 5 mg/kg), surgical intervention if feasible (AII) ^a

IPA invasive pulmonary aspergillosis, AmB amphotericin B, ABLC amphotericin B lipid complex

^a Downgrading compared to IPA (lower patient numbers published)

Table 4 Treatment of *Cryptococcus neoformans* infections in patients with malignancies

Central nervous system:
Very limited data; analogs to HIV-infected patients:
cAmB plus 5-flucytosine or AmB-lipid formulation followed by maintenance therapy with fluconazole: BIII
Voriconazole or posaconazole: CIII
Pulmonary infection:
Fluconazole: AIII
Itraconazole BIII

AmB amphotericin

The recommendations for treatment of zygomycosis are listed in Table 5. An overview of the recommended dosages of antifungal substances is given in Table 6.

Interventional strategies

Surgical intervention

The following may be potential indications for a possible surgical intervention in pulmonary fungal infection: (1) acute hemoptysis, (2) histological diagnostics, (3) removal of residuals prior to the next chemotherapy cycle, and (4) prevention of bleeding in the case of fungal lesions with vessel involvement. Hemoptysis occurs in pulmonary aspergillosis or mucormycosis in up to 30% of cases, frequently during the phase of neutrophil recovery. The fatality rate is approximately 10%. A successful procedure in 18 of 19 patients and a reduction of the mortality from 41% to 14% after introduction of systemic computed tomography (CT)-examinations combined with frequent use of surgical resections has been noted compared to a historical control in a monocenter study [6, 11]. In 41 patients with hematologic diseases undergoing surgical intervention of IPA, the mortality within 30 days was about 10%, fungal relapse occurred in 10%, and the overall survival at 6 months was 65%. Perioperative complications did not influence the outcome [59]. If a patient is considered at high risk for bleeding, i.e., contact of the lesion with the pulmonary artery in the CT scan, a lung resection should follow immediately. The resection of residual infiltrations, combined with antifungal therapy, may result in a local control of the fungal infection in patients requiring further intensive chemotherapy or transplantation [67]. Experience in surgical treatment of IPA, however, are based on the cAmB era; with the new antifungal agents, surgical intervention has less importance. Therefore, we recommend surgical resections for special circumstances, analog to IDSA guidelines (BIII).

Resection recommendations for CNS or sinus mold infections are described elsewhere. In sinonasal aspergillosis, additional surgical intervention may be necessary in

Table 6 Daily dosages of recommended antifungals for treatment of invasive mycosis

Caspofungin: 50 mg, body weight >80 kg: 70 mg
Liver cirrhosis Child–Pugh-Score 7–9: 35 mg, >9: no data
Loading dose day 1: 70 mg
Micafungin: 100 mg
Anidulafungin: 100 mg (loading day 1: 200 mg)
Liposomal AmB: 3 mg/kg
Zygomycosis: at least 5 mg/kg
CNS manifestations: >3 mg/kg
AmB lipid complex: 5 mg/kg
Voriconazole: iv: 2×4 mg/kg; if not tolerable: 2×3 mg/kg;
liver cirrhosis: see below
Creatinine-clearance <50 ml/min: preferably only oral therapy
Loading day 1: 2×6 mg/kg
po: 2×200 mg; body weight <40 kg: 2×100 mg;
liver cirrhosis: see below
Loading: 2×400 mg; body weight <40 kg: 2×200 mg
Liver cirrhosis Child–PughA–B: 50% dosage.
Child–Pugh C: no data
Posaconazole: 2×400 mg; 4×200 mg in case of insufficient
enteral nutrition
Fluconazole: iv/po: 800 mg, switch to 400 mg,
if clinically justified; therapy start preferably with iv-formulation;
creatinin clearance 11–50: 48 h-interval or 50% dosage
Itraconazole: iv: 200 mg, po: 2×200 mg
Loading dose: iv: day 1–2: 2×200 mg;
po: day 1(3)–5: 3–4×200 mg
5-flucytosine: 150 mg/kg divided into 4 doses

individual cases (BIII) [106, 112]. A retrospective study of 81 patients with CNS aspergillosis resulted in significantly better survival in patients undergoing surgery [99]. So, if feasible, surgical resection of singular lesions is recommended (AII).

Drug instillation

For treatment of refractory abscesses or caverns (e.g., in the lungs or brain) in which surgical intervention is not feasible, a drainage, as well as a local drug instillation, can be considered. Here, antifungal preparations (commonly containing AmB) or disinfecting substances such as sodium- or potassium-iodide are administered (CIII).

Embolization

Embolization may be considered in the case of large pulmonary infiltrates where the occurrence of hemoptysis due to vessel erosion is likely, including the development of aneurysms. The vessel involvement of fungal lesions should be diagnosed by a spiral CT. If confirmed, the bronchial and pulmonary vessels can be radiologically embolized (CIII) [37].

Table 5 Therapy of zygomycosis in hematooncologic patients

Lungs:

Liposomal AmB: AII, dosage at least 5 mg/kg: BIII

ABLC: AIII

Posaconazole: AIII

Posaconazole as maintenance therapy in patients with a partial response: CIII

CNS or sinus involvement

Additional surgical intervention, if feasible: BIII

Immunotherapy and granulocyte transfusion

Studies investigating the prophylactic use of granulocyte (-macrophage) colony stimulating factor in hematological patients have shown a definite reduction of the number and severity of bacterial and fungal infections. A benefit from interventional use is not substantiated [68]. The application of hematopoietic growth factor should be considered on an individual case-by-case basis, according to the recommendations of the American Society of Oncology (B III) [103]. Interferon- γ showed a trend to more rapid sterilization of cerebrospinal fluid in cryptococcus meningitis of AIDS patients [76], and the benefit in invasive mycoses after stem cell transplantation is doubtful [97]. Due to the very limited patient numbers, the benefit is not clarified so far (C III). Studies with ligands to toll-like receptors, mycograb (recombinant antibody against *Candida* heat shock protein 90), or adoptive immunotherapy are ongoing [100]. A study from the Perugia Group showed a more rapid reduction in the galactomannan antigen titer and a better outcome in patients with IPA after haploidentical stem cell transplantation (when receiving T cells raised against fungal pathogens) [81]. Further studies with the transfer of immune-effector cells and better tools to determine the numbers of fungus-specific T cells prior and after cellular immunotherapy are urgently required.

Granulocyte transfusions In comparison to the 1980s, the granulocyte harvest and granulocyte function have clearly improved by stimulating the donor with G-CSF. Presently, interventional granulocyte transfusions are being studied in clinical trials. In a retrospective case controlled study on 74 stem cell transplant patients, there was a tendency toward worse outcome in the transfused patients [39]. Another case-controlled study in patients with candidemia showed an equal short-term survival rate, but the group with granulocyte transfusions had higher risk factors, which may be interpreted as a benefit of this option [96]. In 31 patients with invasive fungal infection (17 possible) undergoing granulocyte transfusions, 78% survived [65].

A randomized study with granulocyte transfusion in patients with invasive fungal infections including probable and proven invasive fungal infections during neutropenia after stem cell transplantation or antileukemic therapy had to be closed prematurely due to a dropping recruiting rate after the availability of several new and less toxic antifungal agents. A randomized study with granulocyte transfusion thrice a week in patients with neutropenic fever and pulmonary infiltrates or a history of proven invasive fungal infection (most included episodes were definite or probable invasive fungal infections) failed to confirm the benefit of this procedure [101]. By now, the real benefit of granulocyte transfusion in

invasive mycoses is not doubtlessly clarified [85], but this option may be considered in very severe refractory infection courses (BIII).

References

1. Anaissie E, Bodey GP, Kantarjian H, David C, Barnett K, Bow E (1991) Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. *Am J Med* 91:142–150. doi:10.1016/0002-9343(91)90006-J
2. Anaissie EJ, Darouiche RO, Abi-Said D, Uzun O, Mera J, Gentry LO (1996) Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. *Clin Infect Dis* 23:964–972
3. Anttila VJ, Elonen E, Nordling S, Sivonen A, Ruutu T, Ruutu P (1997) Hepatosplenic candidiasis in patients with acute leukemia: incidence and prognostic implications. *Clin Infect Dis* 24:375–380
4. Baddour LM, Perfect JR, Ostrosky-Zeichner L (2005) Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. *Clin Infect Dis* 40:S409–S413. doi:10.1086/429337
5. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H (1997) A comparison of amphotericin b alone and combined with flucytosine in the treatment of cryptococcal meningitis. *N Engl J Med* 301:126–131
6. Bernard A, Caillot D, Couaillier JF, Casasnovas O, Guy H, Favre JP (1997) Surgical management of invasive pulmonary aspergillosis in neutropenic patients. *Ann Thorac Surg* 64:1441–1447. doi:10.1016/S0003-4975(97)00858-8
7. Böhme A, Ruhnke M, Buchheidt D, Karthaus M, Einsele H, Guth S (2003) Treatment of fungal infections in hematology and oncology—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Ann Hematol* 82(Suppl 2):S133–S140. doi:10.1007/s00277-003-0767-1
8. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ (2004) Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. *Lancet* 363:1764–1767. doi:10.1016/S0140-6736(04)16301-0
9. Van Burik J-AH, Hare RS, Solomon HF, Corrado ML, Kontoyiannis D (2006) Posaconazole is effective as salvage therapy in zygomycosis: A retrospective Summary of 91 cases. *Clin Infect Dis* 42:e61–e65. doi:10.1086/500212
10. Caillot D, Bassaris H, McGeer A, Arthur C, Prentice HG, Seifert W (2001) Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. *Clin Infect Dis* 33:83–90. doi:10.1086/323020
11. Caillot D, Casasnovas O, Bernard A, Couaillier J-F, Durand C, Cuisenier B (1997) Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. *J Clin Oncol* 15:139–147
12. Caillot D, Thiebaut A, Herbrecht R, de Botto S, Pigneux A, Bernard F, Larché J, Monchecourt F, Alfandari S, Mahi L (2007) Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies. *Cancer* 110:2740–2746. doi:10.1002/cncr.23109
13. Chandra J, Zhou G, Ghannoum MA (2005) Fungal biofilms and antimycotics. *Curr Drug Targets* 6:887–894. doi:10.2174/138945005774912762

14. Chandrasekar PH, Ito JI (2005) Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. *Clin Infect Dis* 40(Suppl 6):S392–S400. doi:10.1086/429333
15. Chen CY, Chen YC, Tang JL, Yao M, Huang SY, Tsai W (2003) Hepatosplenic fungal infection in patients with acute leukemia in Taiwan: incidence, treatment, and prognosis. *Ann Hematol* 82:93–97
16. Cordonnier C, Bresnik M, Ebrahimi R (2007) Liposomal amphotericin B (AmBisome R) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis. *Mycoses* 50:205–209. doi:10.1111/j.1439-0507.2007.01362.x
17. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E (2007) Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). *Clin Infect Dis* 44:1289–1297. doi:10.1086/514341
18. Denning DW, Marinus A, Cohen J, Spence D, Herbrecht R, Pagano L (1998) An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. *J Infect* 37:173–180. doi:10.1016/S0163-4453(98)80173-4
19. Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C (2006) Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. *J Infect* 53:337–349. doi:10.1016/j.jinf.2006.03.003
20. Denning DW, Ribaud P, Milpied N, Herbrecht R, Thiel E, Haas A (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. *Clin Infect Dis* 34:563–571. doi:10.1086/324620
21. v. Eiff M, Essink M, Roos N, Hiddemann W, Buchner T, van de Loo J (1990) Hepatosplenic candidiasis, a late manifestation of *Candida septicaemia* in neutropenic patients with haematologic malignancies. *Blut* 60:242–248
22. Einsele H, Bertz H, Beyer J, Kiehl MG, Runde V, Kolb HJ (2003) Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Ann Hematol* 82(Suppl 2):S175–S185. doi:10.1007/s00277-003-0772-4
23. Ellis M, Spence D, de Pauw B, Meunier F, Marinus A, Collette L (1998) An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. *Clin Infect Dis* 27:1406–1412. doi:10.1086/515033
24. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS (2006) Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. *Clin Infect Dis* 43:25–31. doi:10.1086/504810
25. Glasmacher A, Cornely OA, Orlopp K, Reuter S, Blaschke S, Eichel M (2006) Caspofungin treatment in severely ill, immunocompromised patients: a case-documentation study of 118 patients. *J Antimicrob Chemother* 57:127–134. doi:10.1093/jac/dki410
26. Graninger W, Presteril E, Schneeweiss B, Teleky B, Georgopoulos A (1993) Treatment of *Candida albicans* fungaemia with fluconazole. *J Infect* 26:133–146. doi:10.1016/0163-4453(93)92761-K
27. Greenberg RN, Mullane K, van Burik J-AH, Raad I, Abzug MJ, Anstead G (2006) Posaconazole as salvage therapy for zygomycosis. *Antimicrob Agents Chemother* 50:126–133. doi:10.1128/AAC.50.1.126-133.2006
28. Groll AH, Gea-Banacloche JC, Glasmacher A, Just-Nuebling G, Maschmeyer G, Walsh TJ (2003) Clinical pharmacology of antifungal compounds. *Infect Dis Clin North Am* 17:159–191. doi:10.1016/S0891-5520(02)00068-5
29. Groll AH, Giri N, Petraitis V, Petraitiene R, Candelario M, Bacher JS (2000) Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental *Candida albicans* infection of the central nervous system. *J Infect Dis* 182:274–282. doi:10.1086/315643
30. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I (2008) The changing epidemiology of invasive candidiasis. *Cancer* 112:2493–2499. doi:10.1002/cncr.23466
31. Hachem RY, Boktour MR, Hanna HA, Husni RN, Torres HA, Afif C, Kontoyiannis DP, Raad II (2008) Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancies. *Cancer* 112:1282–1287. doi:10.1002/cncr.23311
32. Hachem RY, Kontoyiannis DP, Boktour MR, Afif C, Cooksley C, Bodey GP (2004) *Aspergillus terreus*: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. *Cancer* 101:1594–1600. doi:10.1002/cncr.20554
33. Harbarth S, Burke JP, Lloyd JF, Evans RS, Pestotnik SL, Samore MH (2002) Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. *Clin Infect Dis* 35:e120–e127. doi:10.1086/344468
34. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann J-W (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. *N Engl J Med* 347:408–415. doi:10.1056/NEJMoa020191
35. Herbrecht R, Flückinger U, Gachot B, Ribaud P, Thiebaut A, Cordonnier C (2007) Treatment of invasive *Candida* and *Aspergillus* infections in adult haematological patients. *EJC* 5 (Suppl 2):49–59
36. Herbrecht R, Letscher-Bru V, Bowden RA, Kusne S, Anaissie EJ, Graybill JR (2001) Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. *Eur J Clin Microbiol Infect Dis* 20:460–466
37. Heussel CP, Kauczor HU, Heussel G, Mildenerberger P, Dueber C (1997) Aneurysms complicating inflammatory diseases in immunocompromised hosts: value of contrast-enhanced CT. *Eur Radiol* 7:316–319. doi:10.1007/s003300050157
38. Van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD (1997) Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. *N Engl J Med* 337:15–21. doi:10.1056/NEJM199707033370103
39. Hübel K, Carter RA, Liles WC, Dale DC, Price TH, Bowden RA (2002) Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. *Transfusion* 42:1414–1421. doi:10.1046/j.1537-2995.2002.00249.x
40. Ito JI, Chandrasekar PH, Hooshmand-Rad R (2005) Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA). *Bone Marrow Transplant* 36:873–877. doi:10.1038/sj.bmt.1705143
41. Ito JI, Hooshmand-Rad R (2005) Treatment of *Candida* infections with amphotericin B lipid complex. *Clin Infect Dis* 40(Suppl 6):S384–S391. doi:10.1086/429330
42. Kish MA (2001) Guide to development of practice guidelines. *Clin Infect Dis* 32:851–854. doi:10.1086/319366
43. Kontoyiannis DP, Bodey GP (2002) Invasive aspergillosis in 2002: An update. *Eur J Clin Microbiol Infect Dis* 21:161–172. doi:10.1007/s10096-002-0699-z
44. Kontoyiannis DP, Lewis RE (2003) Combination chemotherapy for invasive fungal infections: what laboratory and clinical

- studies tell us so far. *Drug Resist Updat* 6:257–269. doi:[10.1016/j.drup.2003.08.003](https://doi.org/10.1016/j.drup.2003.08.003)
45. Kontoyiannis DP, Peitsch WK, Reddy BT, Whimbey EE, Han XY, Bodey GP (2001) Cryptococcosis in patients with cancer. *Clin Infect Dis* 32:E145–E150. doi:[10.1086/320524](https://doi.org/10.1086/320524)
 46. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH (2005) Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. *Lancet* 366:1435–1442. doi:[10.1016/S0140-6736\(05\)67490-9](https://doi.org/10.1016/S0140-6736(05)67490-9)
 47. Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D (2007) Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. *Lancet* 369:1519–1527. doi:[10.1016/S0140-6736\(07\)60605-9](https://doi.org/10.1016/S0140-6736(07)60605-9)
 48. Larkin JA, Montero JA (2003) Efficacy and safety of Amphotericin B Lipid Complex for zygomycosis. *Infect Med* 20:201–206
 49. Lass-Flörl C, Griff K, Mayr A, Petzer A, Gastl G, Bonatti H (2005) Epidemiology and outcome of infections due to *Aspergillus terreus*: 10-year single centre experience. *Br J Haematol* 131:201–207. doi:[10.1111/j.1365-2141.2005.05763.x](https://doi.org/10.1111/j.1365-2141.2005.05763.x)
 50. Leenders AC, Daenen S, Jansen RL, Hop WC, Lowenberg B, Wijermans PW (1998) Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. *Br J Haematol* 103:205–212. doi:[10.1046/j.1365-2141.1998.00944.x](https://doi.org/10.1046/j.1365-2141.1998.00944.x)
 51. Leenders AC, Reiss P, Portegies P, Clezy K, Hop WC, Hoy J (1997) Liposomal AmB (AmBisome) compared with AmB both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. *AIDS* 11:1463–1471. doi:[10.1097/00002030-199712000-00010](https://doi.org/10.1097/00002030-199712000-00010)
 52. Leu HS, Huang CT (1995) Clearance of funguria with short-course antifungal regimens: a prospective, randomized, controlled study. *Clin Infect Dis* 20:1152–1157
 53. Lin SJ, Schranz J, Teutsch SM (2001) Aspergillosis case-fatality rate: systematic review of the literature. *Clin Infect Dis* 32:358–366. doi:[10.1086/318483](https://doi.org/10.1086/318483)
 54. Maertens J, Glasmacher A, Herbrecht R, Thiebaut A, Cordonnier C, Segal BH (2006) Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. *Cancer* 107:2888–2897. doi:[10.1002/cncr.22348](https://doi.org/10.1002/cncr.22348)
 55. Maertens J, Raad I, Petrikos G, Boogaerts M, Selleslag D, Petersen FB (2004) Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. *Clin Infect Dis* 39:1563–1571. doi:[10.1086/423381](https://doi.org/10.1086/423381)
 56. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L (2005) Combination antifungal therapy for invasive aspergillosis. *Clin Infect Dis* 39:797–802. doi:[10.1086/423380](https://doi.org/10.1086/423380)
 57. Maschmeyer G, Haas A (2006) Defining clinical failure for salvage studies. *Med Mycol* 44:S315–S318. doi:[10.1080/13693780600835690](https://doi.org/10.1080/13693780600835690)
 58. Maschmeyer G, Haas A, Cornely A (2007) Invasive aspergillosis. Epidemiology, diagnosis and management in immunocompromised patients. *Drugs* 67:1567–1601. doi:[10.2165/00003495-200767110-00004](https://doi.org/10.2165/00003495-200767110-00004)
 59. Matt P, Bernet F, Habicht J (2004) Predicting outcome after lung resection for invasive pulmonary aspergillosis in patients with neutropenia. *Chest* 126:1783–1788. doi:[10.1378/chest.126.6.1783](https://doi.org/10.1378/chest.126.6.1783)
 60. Mattiuzzi G, Giles FJ (2005) Management of intracranial fungal infections in patients with haematological malignancies. *Br J Haematol* 131:287–300. doi:[10.1111/j.1365-2141.2005.05749.x](https://doi.org/10.1111/j.1365-2141.2005.05749.x)
 61. Miller CB, Waller EK, Klingemann HG, Dignani MC, Anaissie EJ, Cagnoni PJ (2004) Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients. *Bone Marrow Transplant* 33:543–548. doi:[10.1038/sj.bmt.1704408](https://doi.org/10.1038/sj.bmt.1704408)
 62. Mills W, Chopra R, Linch DC, Goldstone AH (1994) Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. *Br J Haematol* 86:754–760. doi:[10.1111/j.1365-2141.1994.tb04825.x](https://doi.org/10.1111/j.1365-2141.1994.tb04825.x)
 63. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J (2002) Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. *N Engl J Med* 347:2020–2029. doi:[10.1056/NEJMoa021585](https://doi.org/10.1056/NEJMoa021585)
 64. Morrissey CO, Slavin MA, O'Reilly MA, Daffy JR, Seymour JF, Schwarzer AP (2007) Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: efficacy and concomitant cyclosporin A. *Mycoses* 50(Suppl 1):24–37. doi:[10.1111/j.1439-0507.2007.01377.x](https://doi.org/10.1111/j.1439-0507.2007.01377.x)
 65. Mousset S, Hermann S, Klein SA, Bialleck H, Duchscherer M, Bomke B (2005) Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. *Ann Hematol* 84:734–741. doi:[10.1007/s00277-005-1055-z](https://doi.org/10.1007/s00277-005-1055-z)
 66. Nguyen MH, Peacock JE, Tanner DC, Morris AJ, Nguyen ML, Snyderman DR (1995) Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. *Arch Intern Med* 155:2429–2435. doi:[10.1001/archinte.155.22.2429](https://doi.org/10.1001/archinte.155.22.2429)
 67. Nosari A, Ravini M, Cairoli R, Cozzi P, Marbello L, Marengo P (2007) Surgical resection of persistent pulmonary fungus nodules and secondary prophylaxis are effective in preventing fungal relapse in patients receiving chemotherapy or bone marrow transplantation for leukemia. *Bone Marrow Transplant* 39:631–635. doi:[10.1038/sj.bmt.1705655](https://doi.org/10.1038/sj.bmt.1705655)
 68. Offner F (1997) Hematopoietic growth factors in cancer patients with invasive fungal infections. *Eur J Clin Microbiol Infect Dis* 16:56–63. doi:[10.1007/BF01575122](https://doi.org/10.1007/BF01575122)
 69. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, Mullane KM, Vazquez J, Anaissie EJ (2005) International, open-label, non-comparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. *Eur J Clin Microbiol Infect Dis* 24:654–661. doi:[10.1007/s10096-005-0024-8](https://doi.org/10.1007/s10096-005-0024-8)
 70. Ostrosky-Zeichner L, Lashof A, Kullberg BJ, Rex JH (2003) Voriconazole salvage treatment of invasive candidiasis. *Eur J Clin Microbiol Infect Dis* 22:651–655. doi:[10.1007/s10096-003-1014-3](https://doi.org/10.1007/s10096-003-1014-3)
 71. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH (2003) Amphotericin B: time for a new “gold standard”. *Clin Infect Dis* 37:415–425. doi:[10.1086/376634](https://doi.org/10.1086/376634)
 72. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B (2006) The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. *Haematologica* 91:1068–1075
 73. Pagano L, Caira M, Faluccci P, Fianchi L (2005) Fungal CNS infections in patients with hematologic malignancy. *Expert Rev Anti Infect Ther* 3:775–777. doi:[10.1586/14787210.3.5.775](https://doi.org/10.1586/14787210.3.5.775)
 74. Pagano L, Mele L, Fianchi L, Melillo L, Martino B, D'Antonio D (2002) Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes. *Haematologica* 87:535–541
 75. Pagano L, Ricci P, Offidani M, Fianchi L, Nosari A, Candoni A (2004) Mucormycosis in hematologic patients. *Haematologica* 89:207–214

76. Pappas PG, Bustamante B, Ticona E, Hamill RJ, Johnson PC, Reboli A (2004) Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. *J Infect Dis* 189:2185–2191. doi:[10.1086/420829](https://doi.org/10.1086/420829)
77. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ (2004) Guidelines for treatment of candidiasis. *Clin Infect Dis* 38:161–189. doi:[10.1086/380796](https://doi.org/10.1086/380796)
78. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ (2007) Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. *Clin Infect Dis* 45:883–893. doi:[10.1086/520980](https://doi.org/10.1086/520980)
79. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O (2008) Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. *Clin Infect Dis* 46:201–211. doi:[10.1086/524669](https://doi.org/10.1086/524669)
80. Penack O, Beinert T, Buchheidt D, Einsele H, Hebart H, Kiehl MG (2006) Management of sepsis in neutropenia: guidelines of the infectious diseases working party (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Ann Hematol* 85:424–433. doi:[10.1007/s00277-006-0096-2](https://doi.org/10.1007/s00277-006-0096-2)
81. Perruccio K, Tosti A, Burchielli E, Topini F, Ruggeri L, Carotti L (2005) Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. *Blood* 106:4397–4406. doi:[10.1182/blood-2005-05-1775](https://doi.org/10.1182/blood-2005-05-1775)
82. Phillips P, Shafran S, Garber G, Rotstein C, Smaill F, Fong I (1997) Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. *Eur J Clin Microbiol Infect Dis* 16:337–345. doi:[10.1007/BF01726360](https://doi.org/10.1007/BF01726360)
83. Pitisuttithum P, Negroni R, Graybill JR, Bustamante B, Pappas P, Chapman S (2005) Activity of posaconazole in the treatment of central nervous system fungal infections. *J Antimicrob Chemother* 56:745–755. doi:[10.1093/jac/dki288](https://doi.org/10.1093/jac/dki288)
84. Powderly WG, Saag MS, Cloud GA, Robinson P, Meyer RD, Jacobson JM (1992) A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical trials Group and Mycoses Study Group. *N Engl J Med* 326:793–798
85. Price TH (2007) Granulocyte transfusion: current status. *Semin Hematol* 44:15–23. doi:[10.1053/j.seminhematol.2006.09.015](https://doi.org/10.1053/j.seminhematol.2006.09.015)
86. Raad II, Graybill JR, Bustamante AB, Cornely OA, Gaona-Flores V, Afif C (2006) Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. *Clin Infect Dis* 42:1726–1734. doi:[10.1086/504328](https://doi.org/10.1086/504328)
87. Raad I, Hanna H, Boktour M, Girgawy E, Danawi H, Mardani M (2004) Management of central venous catheters in patients with cancer and candidemia. *Clin Infect Dis* 38:1119–1127. doi:[10.1086/382874](https://doi.org/10.1086/382874)
88. Raad I, Hanna HA, Boktour M, Jiang Y, Afif C, Kontoyiannis DP, Hachem RY (2008) Novel antifungal agents as salvage therapy for invasive aspergilliosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. *Leukemia* 22:496–503. doi:[10.1038/sj.leu.2405065](https://doi.org/10.1038/sj.leu.2405065)
89. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D (2007) Anidulafungin versus fluconazole for invasive candidiasis. *N Engl J Med* 356:2472–2482. doi:[10.1056/NEJMoA066906](https://doi.org/10.1056/NEJMoA066906)
90. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE (1994) A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. *N Engl J Med* 331:1325–1330. doi:[10.1056/NEJM199411173312001](https://doi.org/10.1056/NEJM199411173312001)
91. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S (2003) A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. *Clin Infect Dis* 36:1221–1228. doi:[10.1086/374850](https://doi.org/10.1086/374850)
92. Ringden O, Meunier F, Tollemar J, Ricci P, Tura S, Kuse E (1991) Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. *J Antimicrob Chemother* 28 (suppl B):73–82
93. Roden MR, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL (2005) Epidemiology and outcome of zygomycosis: A review of 929 reported cases. *Clin Infect Dis* 41:634–653. doi:[10.1086/432579](https://doi.org/10.1086/432579)
94. Ruhnke M, Kofla G, Otto K, Schwartz S (2007) CNS aspergilliosis. *CNS Drugs* 21:659–676. doi:[10.2165/00023210-200721080-00004](https://doi.org/10.2165/00023210-200721080-00004)
95. Saag MS, Graybill RJ, Larsen RA (2000) Practice guidelines for the management of cryptococcal disease. *Clin Infect Dis* 30:710–717. doi:[10.1086/313757](https://doi.org/10.1086/313757)
96. Safdar A, Hanna HA, Boktour M, Kontoyiannis DP, Hachem R, Lichtiger B (2004) Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of *Candida* species bloodstream infections. *Cancer* 101:2859–2865. doi:[10.1002/cncr.20710](https://doi.org/10.1002/cncr.20710)
97. Safdar A, Rodriguez G, Ohmagari N, Kontoyiannis DP, Rolston KV, Raad II (2005) The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation. *Cancer* 103:731–739. doi:[10.1002/cncr.20883](https://doi.org/10.1002/cncr.20883)
98. Sallah S, Semelka RC, Wehbie R, Sallah W, Nguyen NP, Vos P (1999) Hepatosplenic candidiasis in patients with acute leukaemia. *Br J Haematol* 106:697–701. doi:[10.1046/j.1365-2141.1999.01592.x](https://doi.org/10.1046/j.1365-2141.1999.01592.x)
99. Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA (2005) Improved outcome in central nervous system aspergilliosis, using voriconazole treatment. *Blood* 106:2641–2645. doi:[10.1182/blood-2005-02-0733](https://doi.org/10.1182/blood-2005-02-0733)
100. Segal BH, Kwon-Chung J, Walsh TJ, Klein BS, Battiwalla M, Almyroudis NG (2006) Immunotherapy for fungal infections. *Clin Infect Dis* 42:507–515. doi:[10.1086/499811](https://doi.org/10.1086/499811)
101. Seidel MG, Peters C, Wacker A, Northoff H, Moog R, Böhme A et al. (2008) Randomized phase III study of granulocyte transfusions in neutropenic patients. *Bone Marrow Transplant* (in press)
102. DeShazo RD, Chapin K, Swain RE (1997) Fungal sinusitis. *N Engl J Med* 337:254–259. doi:[10.1056/NEJM199707243370407](https://doi.org/10.1056/NEJM199707243370407)
103. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. *J Clin Oncol* 24:3187–3205. doi:[10.1200/JCO.2006.06.4451](https://doi.org/10.1200/JCO.2006.06.4451)
104. Sobel JD, Kauffman CA, McKinsey D, Zervos M, Vazquez JA, Karchmer AW (2000) Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. *Clin Infect Dis* 30:19–24. doi:[10.1086/313580](https://doi.org/10.1086/313580)
105. Spellberg BJ, Filler SG, Edwards JE (2006) Current treatment strategies for disseminated candidiasis. *Clin Infect Dis* 42:244–251. doi:[10.1086/499057](https://doi.org/10.1086/499057)
106. Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW (2000) Practice guidelines for diseases caused by *Aspergillus*. Infectious Diseases Society of America. *Clin Infect Dis* 30:696–709. doi:[10.1086/313756](https://doi.org/10.1086/313756)

107. Tedder M, Spratt JA, Anstadt MP, Hedge SS, Tedder SD, Lowe JE (1994) Pulmonary mucormycosis: results of medical and surgical therapy. *Ann Thorac Surg* 57:1044–1050
108. Ullmann AJ, Sanz MA, Tramarin A, Barnes RA, Wu W, Gerlach BA (2006) Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. *Clin Infect Dis* 43:e29–e38. doi:[10.1086/505969](https://doi.org/10.1086/505969)
109. Viollier AF, Peterson DE, De Jongh CA, Newman KA, Gray WC, Sutherland JC (1986) Aspergillus sinusitis in cancer patients. *Cancer* 58:366–371. doi:[10.1002/1097-0142\(19860715\)58:2<366::AID-CNCR2820580228>3.0.CO;2-V](https://doi.org/10.1002/1097-0142(19860715)58:2<366::AID-CNCR2820580228>3.0.CO;2-V)
110. Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B (1999) Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). *Clin Infect Dis* 28:1071–1079. doi:[10.1086/514731](https://doi.org/10.1086/514731)
111. Walsh TJ (1998) Primary cutaneous aspergillosis —an emerging infection among immunocompromised patients. *Clin Infect Dis* 27:453–457. doi:[10.1086/514718](https://doi.org/10.1086/514718)
112. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. *Clin Infect Dis* 46:327–360. doi:[10.1086/525258](https://doi.org/10.1086/525258)
113. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R (2007) Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. *Clin Infect Dis* 44:2–12. doi:[10.1086/508774](https://doi.org/10.1086/508774)
114. Wolf HH, Leithäuser M, Maschmeyer G, Salwender H, Klein U, Chaberny I et al. (2008) Central venous catheter-related infections in hematology and oncology: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Ann Hematol* 87:863–876